Sarah Cannon Research Institute, Nashville, TN 37203, USA.
Oncologist. 2010;15(11):1227-37. doi: 10.1634/theoncologist.2009-0090. Epub 2010 Nov 2.
Radiation recall is an acute inflammatory reaction confined to previously irradiated areas that can be triggered when chemotherapy agents are administered after radiotherapy. It remains a poorly understood phenomenon, but increased awareness may aid early diagnosis and appropriate management. A diverse range of drugs used in the treatment of cancer has been associated with radiation recall. As most data come from case reports, it is not possible to determine the true incidence, but to date the antineoplastic drugs for which radiation recall reactions have been most commonly reported include the anthracycline doxorubicin, the taxanes docetaxel and paclitaxel, and the antimetabolites gemcitabine and capecitabine. Radiation recall is drug-specific for any individual patient; it is not possible to predict which patients will react to which drugs, and rechallenge does not uniformly induce a reaction. There are no identifiable characteristics of drugs that cause radiation recall, and thus, it is a possibility that must be kept in mind with use of any drug after radiotherapy, including those from new drug classes. Although it is not yet possible to design treatment regimens to eliminate the risk of radiation recall, it seems likely that risks can be minimized by prolonging the interval between completion of radiotherapy and initiation of chemotherapy.
放射性回忆是一种局限于先前照射区域的急性炎症反应，当放射治疗后给予化疗药物时可能会引发。它仍然是一个尚未被充分理解的现象，但提高认识可能有助于早期诊断和适当的管理。在治疗癌症中使用的各种药物已与放射性回忆相关联。由于大多数数据来自病例报告，因此无法确定真实的发生率，但迄今为止，放射性回忆反应最常报道的抗肿瘤药物包括蒽环类药物多柔比星、紫杉烷类药物多西他赛和紫杉醇以及抗代谢药物吉西他滨和卡培他滨。对于任何个体患者，放射性回忆是药物特异性的；不可能预测哪些患者会对哪些药物产生反应，而且再次用药并不一定会均匀地引起反应。引起放射性回忆的药物没有可识别的特征，因此，在放射治疗后使用任何药物（包括新型药物类别）时都必须考虑到这种可能性。虽然目前还不可能设计治疗方案来消除放射性回忆的风险，但似乎可以通过延长放射治疗完成和化疗开始之间的间隔来最小化风险。
